NewLimit Raises $435 Million Series C Ahead of First Clinical Trial for Longevity Medicine

NewLimit announced a $435 million Series C funding round on June 2, 2026, led by Founders Fund with participation from Thrive Capital, Lilly Ventures, Nat Friedman, and Daniel Gross. The South San Francisco longevity biotech, valued at around $3.1 billion, plans to launch its first clinical trial of a liver medicine. Founded in 2021 by Coinbase CEO Brian Armstrong, Blake Byers, and Jacob Kimmel, NewLimit previously raised $130 million in May 2025.

Series C funding round

• ▪NewLimit's Series C funding round included participation from Thrive Capital, Lilly Ventures, Nat Friedman, and Daniel Gross
• ▪NewLimit raised $435 million in a Series C funding round
• ▪NewLimit announced its Series C fundraising on June 2, 2026
• ▪NewLimit plans to launch its first clinical trial of a liver medicine
• ▪Founders Fund led NewLimit's Series C financing round

Company background

• ▪NewLimit is based in South San Francisco
• ▪Blake Byers is a former GV partner and bioengineer
• ▪Brian Armstrong is the CEO and co-founder of Coinbase
• ▪NewLimit was founded in 2021 by Brian Armstrong, Blake Byers, and Jacob Kimmel
• ▪Jacob Kimmel is a stem cell biologist
• ▪Founders Fund is a Silicon Valley venture capital firm co-founded by Peter Thiel
• ▪NewLimit is valued at around $3.1 billion according to co-founder and CEO Jacob Kimmel

Rapid fundraising timeline

• ▪NewLimit raised $45 million in October 2025
• ▪NewLimit announced three fundraising rounds in the last year
• ▪NewLimit raised a $130 million Series B round in May 2025